Neurotrophin-3 improves functional constipation

Henry P. Parkman, Satish S.C. Rao, James C. Reynolds, Lawrence R. Schiller, Arnold Wald, Philip B. Miner, Anthony J. Lembo, James M. Gordon, Douglas A. Drossman, Lynn Waltzman, Nancy Stambler, Jesse M. Cedarbaum

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

OBJECTIVE: Neurotrophin-3 (NT-3) is a neurotrophic factor involved in the growth, development, and function of the nervous system. In preliminary studies, s.c. recombinant methionyl-human NT-3 enhanced transit throughout the GI tract and increased stool frequency in normal and constipated subjects. Our aim was to assess 1) the dose-related effects of NT-3 on bowel function, colon transit, and symptoms of chronic constipation, and 2) its safety. METHODS: This was a double-blind, randomized, placebo-controlled phase II study. A total of 107 patients with a diagnosis of functional constipation (Rome II criteria) were randomized to receive 4 wk of double blind, s.c. injections of either placebo, 3 mg, or 9 mg NT-3 once per week (qW) or three times per week (TTW); or 9 mg NT-3 TTW for 1 wk, then qW. The primary endpoint was the change in number of spontaneous, complete bowel movements per week. Colon transit was assessed before and at end of treatment. RESULTS: Compared with placebo, patients who received 9 mg NT-3 TTW showed significant increases in frequency of spontaneous, complete bowel movements and total bowel movements, as well as dose-related softening of stool and improved ease of passage. The number of days per week without a bowel movement also decreased, colon transit improved, as did constipation-related symptoms. Weekly dosing was ineffective. Transient injection-site reactions, seen in one third of patients receiving NT-3 TTW, were the most frequent adverse event. CONCLUSIONS: NT-3, administered TTW, increased stool frequency, enhanced colon transit, and improved symptoms of chronic constipation. NT-3 seems to be a novel, safe, and effective agent for the treatment of functional constipation.

Original languageEnglish (US)
Pages (from-to)1338-1347
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume98
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Neurotrophin 3
Constipation
Colon
Placebos
Injections
Nerve Growth Factors
Growth and Development
Nervous System
Gastrointestinal Tract
Safety

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Parkman, H. P., Rao, S. S. C., Reynolds, J. C., Schiller, L. R., Wald, A., Miner, P. B., ... Cedarbaum, J. M. (2003). Neurotrophin-3 improves functional constipation. American Journal of Gastroenterology, 98(6), 1338-1347. https://doi.org/10.1111/j.1572-0241.2003.t01-1-07477.x

Neurotrophin-3 improves functional constipation. / Parkman, Henry P.; Rao, Satish S.C.; Reynolds, James C.; Schiller, Lawrence R.; Wald, Arnold; Miner, Philip B.; Lembo, Anthony J.; Gordon, James M.; Drossman, Douglas A.; Waltzman, Lynn; Stambler, Nancy; Cedarbaum, Jesse M.

In: American Journal of Gastroenterology, Vol. 98, No. 6, 01.06.2003, p. 1338-1347.

Research output: Contribution to journalArticle

Parkman, HP, Rao, SSC, Reynolds, JC, Schiller, LR, Wald, A, Miner, PB, Lembo, AJ, Gordon, JM, Drossman, DA, Waltzman, L, Stambler, N & Cedarbaum, JM 2003, 'Neurotrophin-3 improves functional constipation', American Journal of Gastroenterology, vol. 98, no. 6, pp. 1338-1347. https://doi.org/10.1111/j.1572-0241.2003.t01-1-07477.x
Parkman, Henry P. ; Rao, Satish S.C. ; Reynolds, James C. ; Schiller, Lawrence R. ; Wald, Arnold ; Miner, Philip B. ; Lembo, Anthony J. ; Gordon, James M. ; Drossman, Douglas A. ; Waltzman, Lynn ; Stambler, Nancy ; Cedarbaum, Jesse M. / Neurotrophin-3 improves functional constipation. In: American Journal of Gastroenterology. 2003 ; Vol. 98, No. 6. pp. 1338-1347.
@article{df2f534e4808469fabe772d001e1a993,
title = "Neurotrophin-3 improves functional constipation",
abstract = "OBJECTIVE: Neurotrophin-3 (NT-3) is a neurotrophic factor involved in the growth, development, and function of the nervous system. In preliminary studies, s.c. recombinant methionyl-human NT-3 enhanced transit throughout the GI tract and increased stool frequency in normal and constipated subjects. Our aim was to assess 1) the dose-related effects of NT-3 on bowel function, colon transit, and symptoms of chronic constipation, and 2) its safety. METHODS: This was a double-blind, randomized, placebo-controlled phase II study. A total of 107 patients with a diagnosis of functional constipation (Rome II criteria) were randomized to receive 4 wk of double blind, s.c. injections of either placebo, 3 mg, or 9 mg NT-3 once per week (qW) or three times per week (TTW); or 9 mg NT-3 TTW for 1 wk, then qW. The primary endpoint was the change in number of spontaneous, complete bowel movements per week. Colon transit was assessed before and at end of treatment. RESULTS: Compared with placebo, patients who received 9 mg NT-3 TTW showed significant increases in frequency of spontaneous, complete bowel movements and total bowel movements, as well as dose-related softening of stool and improved ease of passage. The number of days per week without a bowel movement also decreased, colon transit improved, as did constipation-related symptoms. Weekly dosing was ineffective. Transient injection-site reactions, seen in one third of patients receiving NT-3 TTW, were the most frequent adverse event. CONCLUSIONS: NT-3, administered TTW, increased stool frequency, enhanced colon transit, and improved symptoms of chronic constipation. NT-3 seems to be a novel, safe, and effective agent for the treatment of functional constipation.",
author = "Parkman, {Henry P.} and Rao, {Satish S.C.} and Reynolds, {James C.} and Schiller, {Lawrence R.} and Arnold Wald and Miner, {Philip B.} and Lembo, {Anthony J.} and Gordon, {James M.} and Drossman, {Douglas A.} and Lynn Waltzman and Nancy Stambler and Cedarbaum, {Jesse M.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1111/j.1572-0241.2003.t01-1-07477.x",
language = "English (US)",
volume = "98",
pages = "1338--1347",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Neurotrophin-3 improves functional constipation

AU - Parkman, Henry P.

AU - Rao, Satish S.C.

AU - Reynolds, James C.

AU - Schiller, Lawrence R.

AU - Wald, Arnold

AU - Miner, Philip B.

AU - Lembo, Anthony J.

AU - Gordon, James M.

AU - Drossman, Douglas A.

AU - Waltzman, Lynn

AU - Stambler, Nancy

AU - Cedarbaum, Jesse M.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - OBJECTIVE: Neurotrophin-3 (NT-3) is a neurotrophic factor involved in the growth, development, and function of the nervous system. In preliminary studies, s.c. recombinant methionyl-human NT-3 enhanced transit throughout the GI tract and increased stool frequency in normal and constipated subjects. Our aim was to assess 1) the dose-related effects of NT-3 on bowel function, colon transit, and symptoms of chronic constipation, and 2) its safety. METHODS: This was a double-blind, randomized, placebo-controlled phase II study. A total of 107 patients with a diagnosis of functional constipation (Rome II criteria) were randomized to receive 4 wk of double blind, s.c. injections of either placebo, 3 mg, or 9 mg NT-3 once per week (qW) or three times per week (TTW); or 9 mg NT-3 TTW for 1 wk, then qW. The primary endpoint was the change in number of spontaneous, complete bowel movements per week. Colon transit was assessed before and at end of treatment. RESULTS: Compared with placebo, patients who received 9 mg NT-3 TTW showed significant increases in frequency of spontaneous, complete bowel movements and total bowel movements, as well as dose-related softening of stool and improved ease of passage. The number of days per week without a bowel movement also decreased, colon transit improved, as did constipation-related symptoms. Weekly dosing was ineffective. Transient injection-site reactions, seen in one third of patients receiving NT-3 TTW, were the most frequent adverse event. CONCLUSIONS: NT-3, administered TTW, increased stool frequency, enhanced colon transit, and improved symptoms of chronic constipation. NT-3 seems to be a novel, safe, and effective agent for the treatment of functional constipation.

AB - OBJECTIVE: Neurotrophin-3 (NT-3) is a neurotrophic factor involved in the growth, development, and function of the nervous system. In preliminary studies, s.c. recombinant methionyl-human NT-3 enhanced transit throughout the GI tract and increased stool frequency in normal and constipated subjects. Our aim was to assess 1) the dose-related effects of NT-3 on bowel function, colon transit, and symptoms of chronic constipation, and 2) its safety. METHODS: This was a double-blind, randomized, placebo-controlled phase II study. A total of 107 patients with a diagnosis of functional constipation (Rome II criteria) were randomized to receive 4 wk of double blind, s.c. injections of either placebo, 3 mg, or 9 mg NT-3 once per week (qW) or three times per week (TTW); or 9 mg NT-3 TTW for 1 wk, then qW. The primary endpoint was the change in number of spontaneous, complete bowel movements per week. Colon transit was assessed before and at end of treatment. RESULTS: Compared with placebo, patients who received 9 mg NT-3 TTW showed significant increases in frequency of spontaneous, complete bowel movements and total bowel movements, as well as dose-related softening of stool and improved ease of passage. The number of days per week without a bowel movement also decreased, colon transit improved, as did constipation-related symptoms. Weekly dosing was ineffective. Transient injection-site reactions, seen in one third of patients receiving NT-3 TTW, were the most frequent adverse event. CONCLUSIONS: NT-3, administered TTW, increased stool frequency, enhanced colon transit, and improved symptoms of chronic constipation. NT-3 seems to be a novel, safe, and effective agent for the treatment of functional constipation.

UR - http://www.scopus.com/inward/record.url?scp=0037973518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037973518&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2003.t01-1-07477.x

DO - 10.1111/j.1572-0241.2003.t01-1-07477.x

M3 - Article

C2 - 12818279

AN - SCOPUS:0037973518

VL - 98

SP - 1338

EP - 1347

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -